Acoziborole for trypanosomiasis, african

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 11 Oct 2016: Trial started, NCT03087955
  2. 23 Mar 2017: Trial registered, NCT03087955
  3. 30 Dec 2021: Trial started, NCT05256017
  4. 25 Feb 2022: Trial registered, NCT05256017
  5. 27 Jun 2022: Trial registered, NCT05433350
  6. 9 Jul 2022: Trial started, NCT05433350

The trials

NCT03087955: Efficacy and Safety of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis Due to T.b. Gambiense

State
Completed
Phase
Phase 2 and Phase 3
People
208 taking part
Started
11 Oct 2016
Primary completion
8 Sep 2020
Arms
Late-stage HAT, Early- and intermediate-stage HAT
Results
Posted on the registry
  1. 11 Oct 2016: Trial started
  2. 23 Mar 2017: Trial registered
  3. 8 Sep 2020: Trial completed
  4. 17 Sep 2025: Trial results posted

NCT05256017: Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects

State
Completed
Phase
Phase 2 and Phase 3
People
1,208 taking part
Started
30 Dec 2021
Primary completion
3 Aug 2023
Arms
Acoziborole
Results
Posted on the registry
  1. 30 Dec 2021: Trial started
  2. 25 Feb 2022: Trial registered
  3. 3 Aug 2023: Trial completed
  4. 20 Mar 2025: Trial results posted

NCT05433350: Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients

State
Completed
Phase
Phase 2 and Phase 3
People
35 taking part
Started
9 Jul 2022
Primary completion
31 Mar 2026
Arms
Acoziborole
Results
None posted
  1. 27 Jun 2022: Trial registered
  2. 9 Jul 2022: Trial started
  3. 31 Mar 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.